Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide Lym-X-Sorb for insulin sensitivity in obese insulin-resistant postmenopausal women
NL-OMON37344Phase 2Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fenretinide in insulin resistance (IR), obesity and type 2 diabetes mellitus (T2DM), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in hepatic insulin sensitivity and Change in peripheral insulin sensitivity. Planned start Feb 2012; status: withdrawn.
02
Drugs
fenretinide
03
Conditions
insulin resistance (IR)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON37344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37344.